arrow
A

Angelo Minucci

Fondazione Policlinico Universitario A. Gemelli IRCCS
H指数:31
被引数:3,420

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort

浅表转移的高发生率支持经皮超声引导活检用于晚期肺癌的诊断和分子分型:一项前瞻性队列研究的结果

Cancers
IF4.4
2026-07-230
OA
Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach

IA期2级子宫内膜样子宫内膜癌的保留生育功能治疗:标准化方法的治疗效果

2026-07-080
OAAI
LANTERN 2: Association Between Gene Molecular Profile and STAS in Lung Adenocarcinoma: A Comparative Analysis in a Prospective Real-World Population

LANTERN 2:基因分子图谱与肺腺癌STAS之间的关联:一项前瞻性真实世界人群的比较分析

Genes
IF2.8
2026-06-090
OA
Enhanced Detection of BRCA Copy Number Alterations Within a Commercial HRD Assay: Implications for Precision Oncology in Ovarian Cancer

BRCA拷贝数改变在商业HRD检测中的增强检测:对卵巢癌精准肿瘤学的意义

2026-04-290
OAAI
LANTERN-XGB: An Interpretable Multi-Modal Machine Learning for Improving Clinical Decision-Making in Lung Cancer

LANTERN-XGB:一种可解释的多模态机器学习方法,用于改善肺癌临床决策制定

2026-03-310
OAAI
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions

液体活检在非转移性前列腺癌中的应用:临床证据与未来方向

Cancers
IF4.4
2026-03-010
OAAI
Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study

临床意义显著BRCA大基因组重排的检测:一项比较NGS研究(在FFPE卵巢癌样本中)

2025-10-010
OAAI
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer

根据分子靶点临床可操作性量表(ESCAT)评估的,无特定分子特征(NSMP)子宫内膜癌的基因可操作性

2025-09-030
OAAI
Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement

液体活检在前列腺癌中的应用:多学科专家共识声明

2025-09-010
PRE
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib

NRG1变异体不确定意义(VUSes)在晚期非小细胞肺癌中的网络分析及其在EGFR突变患者接受一线奥希替尼治疗中的预后作用

2025-08-290
OAAI
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据BRCA1/2突变类型和位点,在新诊断卵巢癌患者中从PARP抑制剂维持治疗中获益:一项多中心真实世界研究

2025-04-011
OAAI
Mesonephric-like adenocarcinoma of the endometrium: detailed molecular characterization of the first case showing a morphological continuum from mesonephric-like metaplasia and atypical mesonephric-like hyperplasia to adenocarcinoma
2025-02-140
PRE